A critical question for men with favorable intermediate-risk prostate cancer (based primarily on a Gleason score of 3 + 4 = 7) can often be, “How safe would it be for me to go on active surveillance for a while after initial diagnosis?” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, outcomes, risk, surgery | 1 Comment »
The increasingly widespread use of testosterone supplements has been of concern for many years. In particular, for men with a history of prostate cancer diagnosis, the appropriate use of testosterone supplementation has been a matter of special focus. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: deficiency, Diagnosis, evaluation, testosterone, Treatment | 3 Comments »
A new report in the journal JAMA Surgery has suggested that urologists who see fewer patients tend to get higher satisfaction ratings than those with higher-volume practices. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: care, perception, quality, satisfaction, urologist | 2 Comments »
According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, lutetium-177, outcome, Phase III, pivotal, PSMA-617, safety, trial | 4 Comments »
About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", ADT, androgen, deprivation, mitoxantrone, outcome, prednisone, survival | 3 Comments »
Once again your sitemaster finds himself flabbergasted at just how often we need to repeat similar experiments to prove the obvious. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, diet, exercise, quality of life | 6 Comments »
We have known for some time that taking abiraterone acetate (Zytiga) with food (as opposed to on an empty stomach) might well allow patients to be able to take significantly lower doses of this product and gain the same clinical benefit as is currently known to be beneficial from taking 1,000 mg/day when fasting. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, dose, food, low, standard, with, without | 5 Comments »
